Literature DB >> 8135874

Veinotonic effect, vascular protection, antiinflammatory and free radical scavenging properties of horse chestnut extract.

M Guillaume1, F Padioleau.   

Abstract

Horse chestnut extract (HCE), containing 70% escin, is the main active component of Veinotonyl 75. The aim of this work was to investigate pharmacological properties attempting to elucidate the efficacy of HCE in chronic venous insufficiency. Veinotonic and lymphagogue properties: HCE dose dependently contracts the canine saphenous isolated vein (cumulative doses 5 x 10(-8) to 5 x 10(-4) g/ml). Its action lasts more than 5 h. In the perfused canine saphenous vein, HCE (25-50 mg in bolus) increases the venous pressure of the normal vein and the pathological vein stenosed 8 days before, and the contractile response to noradrenaline is significantly potentiated. Moreover, during the perfusion in inverse direction of the blood stream, a clear contracting effect on the valves is also obtained with HCE. In the anaesthetized dog, HCE in situ improves the femoral vein compliance and opposes the venous distension obtained during clamping in a carotido-femoral perfusion with constant flow. In other respects, HCE significantly increases femoral venous pressure and flow, together with thoracic lymphatic flow, while respecting the arterial parameters (2.5 and 5 mg/kg i.v.). Vasculotropic action: HCE dose dependently diminishes the cutaneous capillary hyperpermeability induced either by injections of phlogistic agents as histamine and serotonin in the rat (100 to 400 mg/kg p.o.), or by an irritative agent (chloroform) application in the rabbit (50 to 300 mg/kg p.o. and 2.5 to 5 mg/kg i.v.). It significantly increases the vascular resistance in the guinea pig fed a scorbutigenic diet as measured by the petechia method (50 to 400 mg/kg p.o.). Antiedema and antiinflammatory properties: HCE decreases the formation of edemas induced in the rat's hind paw, one of lymphatic origin, the other of inflammatory origin (200 to 400 mg/kg p.o.). In an experimental model of pleurisy in the rat HCE suppresses plasmatic extravasation and leucocytes emigration into the pleural cavity (200 to 400 mg/kg p.o.; 1 to 10 mg/kg i.v.). It decreases the connective tissue formation in the subchronic model of inflammatory granuloma in the rat (400 mg/kg p.o. and 5-10 mg/kg s.c.). Antiradical mechanism of action both in vitro and in vivo: HCE dose dependently inhibits both enzymatic and non-enzymatic in vitro lipid peroxidation (5 x 10(-6) to 5 x 10(-4) g/ml).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8135874

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  11 in total

Review 1.  Dietary supplements and cardiovascular disease.

Authors:  R M DeBusk
Journal:  Curr Atheroscler Rep       Date:  2000-11       Impact factor: 5.113

Review 2.  Drug treatment of haemorrhoids.

Authors:  Mahesh C Misra
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Escin: inhibiting inflammation and promoting gastrointestinal transit to attenuate formation of postoperative adhesions.

Authors:  Fenghua Fu; Yuezhi Hou; Wanglin Jiang; Ronghua Wang; Ke Liu
Journal:  World J Surg       Date:  2005-12       Impact factor: 3.352

4.  Pilot postoperative ileus study of escin in cancer patients after colorectal surgery.

Authors:  Qiwei Xie; Xianglong Zong; Baoming Ge; Shan Wang; Jiafu Ji; Yingjiang Ye; Lili Pan
Journal:  World J Surg       Date:  2009-02       Impact factor: 3.352

5.  Beta-escin has potent anti-allergic efficacy and reduces allergic airway inflammation.

Authors:  Ines Lindner; Christiane Meier; Angelika Url; Hermann Unger; Andreas Grassauer; Eva Prieschl-Grassauer; Petra Doerfler
Journal:  BMC Immunol       Date:  2010-05-21       Impact factor: 3.615

6.  Rutosides for prevention of post-thrombotic syndrome.

Authors:  Joanne R Morling; Su Ern Yeoh; Dinanda N Kolbach
Journal:  Cochrane Database Syst Rev       Date:  2018-11-08

7.  Rutosides for treatment of post-thrombotic syndrome.

Authors:  Joanne R Morling; Cathryn Broderick; Su Ern Yeoh; Dinanda N Kolbach
Journal:  Cochrane Database Syst Rev       Date:  2018-11-08

8.  The positive clinical therapeutically effects of Escin on advanced thyroid cancer.

Authors:  Jin-Yu Mei; Ming-Jun Zhang; Yuan-Yuan Wang; Ye-Hai Liu
Journal:  Cancer Med       Date:  2017-04-04       Impact factor: 4.452

9.  Molecular Mechanism for Cellular Response to β-Escin and Its Therapeutic Implications.

Authors:  Dominik Domanski; Oliwia Zegrocka-Stendel; Anna Perzanowska; Malgorzata Dutkiewicz; Magdalena Kowalewska; Iwona Grabowska; Dorota Maciejko; Anna Fogtman; Michal Dadlez; Katarzyna Koziak
Journal:  PLoS One       Date:  2016-10-11       Impact factor: 3.240

Review 10.  Horse chestnut seed extract for chronic venous insufficiency.

Authors:  Max H Pittler; Edzard Ernst
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.